Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease. Your doctor might suggest taking ...

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...

In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from ...

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

M Health Fairview now offers both Alzheimer's infusion treatments — lecanemab and donanemab — both of which slow the ...

Lecanemab's maintenance dosing regimen is now approved for early-stage Alzheimer's, transitioning from biweekly to once every four weeks after 18 months. Phase 2 and 3 trials confirmed lecanemab's ...